

Ismidenon
CAS 887603-94-3
MF C15H12N2O MW236.27 g/mol
spiro(imidazo-(1,2-a)pyridine-3,2-indan)-2(3H)-one
1′,3′-dihydro-2H-spiro[imidazo[1,2-a]pyridine-3,2′-inden]-2-one
voltage-dependent T-type calcium channel modulator, ZSET 1446, ST 101, 7TTT61784C
ST-101 is a small peptide antagonist of C/EBPβ and T-type calcium channel activator. ST101 has been used in trials studying the treatment of Essential Tremor and Alzheimer’s Disease.
Ismidenon is an orally bioavailable azaindolizinone derivative and acetylcholine releasing agent, with potential neurocognitive-enhancing activity. Upon oral administration, ismidenon increases acetylcholine release in the central nervous system (CNS), thereby enhancing cholinergic neurotransmission. Ismidenon also decreases amyloid beta peptide production. This may improve neurocognitive function in Alzheimer’s disease.
- Evaluating the Pharmacokinetic Characteristics of AD-101 in Healthy VolunteersCTID: NCT03764462Phase: Phase 1Status: CompletedDate: 2019-08-30
- A Pilot Efficacy and Safety Study of ST101 in Essential TremorCTID: NCT01332695Phase: Phase 2Status: CompletedDate: 2012-01-06
- A Phase 1-2 Study of ST101 in Patients With Advanced Solid TumorsCTID: NCT04478279Phase: Phase 1/Phase 2Status: Active, not recruitingDate: 2025-05-11
- Preliminary Efficacy and Safety Study of ST101 in Alzheimer’s DiseaseCTID: NCT00842673Phase: Phase 2Status: CompletedDate: 2012-06-07
- Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer’s DiseaseCTID: NCT00842816Phase: Phase 2Status: CompletedDate: 2012-06-07
SYN
PAT
[ 0149 ]
spiro[imidazo[l,2-a]pyridin-2(3H)-one-3,2′-indan] (Compound 24)

[ 0150 ]
Melting Point: 206 0C (decomposition);
NMR (CDCh) δ: 3.16 (2H, d, J=16Hz), 3.89 (2H, d, J=16Hz), 6.49 (IH, t, J=7Hz), 7.1-7.2
(2H, m), 7.2-7.3 (4H, m), 7.61 (IH, t, J=7Hz);
MS m/z: 236 (M+).
PAT
- Heterocyclic compounds and cerebral function improvers containing the same as the active ingredientPublication Number: US-7767824-B2Priority Date: 2001-01-30Grant Date: 2010-08-03
- Azaindolizinone derivatives and cognitive enhancers comprising the same as effective componentsPublication Number: EP-1219621-B1Priority Date: 1999-07-30Grant Date: 2003-10-22
- Azaindolizinone derivatives and cerebral function improvers containing the same as the active ingredientPublication Number: US-6635652-B1Priority Date: 1999-07-30Grant Date: 2003-10-21
- Azaindolizinone derivatives and cerebral function improvers containing the same as the active ingredientPublication Number: EP-1219621-A1Priority Date: 1999-07-30



AS ON OCT2025 4.511 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE

join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com

……
///////ismidenon, voltage-dependent T-type calcium channel modulator, ZSET 1446, ST 101, 7TTT61784C
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....
